trending Market Intelligence /marketintelligence/en/news-insights/trending/dfzJPKfofW8sfzqJ61Sw3A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Eli Lilly, Dicerna closes collaboration on RNA interference therapies

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Eli Lilly, Dicerna closes collaboration on RNA interference therapies

Eli Lilly and Co. and Dicerna Pharmaceuticals Inc.'s licensing and research collaboration on RNA interference therapies closed after receiving U.S. antitrust clearance.

RNA interference, or RNAi, is a biologic process in which certain double-stranded RNA molecules hinder the expression of disease-causing genes.

The collaboration has been cleared under the Hart-Scott-Rodino Act, which means the deal has received antitrust clearance.

Indianapolis-based Eli Lilly and Dicerna previously agreed to use the latter's GalXC RNAi platform to develop new drug targets in the areas of cardio-metabolic disease, neurodegeneration and pain. The companies plan to collaborate on over 10 targets.

The deal involves Lilly paying Dicerna $100 million up front and making an equity investment of $100 million in the Cambridge, Mass.-based company at a premium.